Analysis of olaparib for ovarian, fallopian tube and primary peritoneal cancer, June 2023
Page last updated: 14 November 2023
Drug utilisation sub-committee (DUSC)
June 2023
Abstract
Purpose
To review the utilisation of olaparib for ovarian, fallopian tube and primary peritoneal cancer as requested by DUSC at its February 2023 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Olaparib was first PBS-listed for the second-line treatment of high grade serous ovarian, primary peritoneal and serous fallopian tube cancer on 1 February 2017.
Data Source / methodology
Data extracted from the PBS and Date of Death database maintained by the Department of Health and Aged Care, processed by Services Australia were used for the analyses.
Key Findings
- In 2022, 598 patients were treated with olaparib and supplied 4,864 prescriptions.
- In 2021, 543 patients were treated with olaparib and supplied 4,363 prescriptions.
- In 2021 and 2022, there was a greater proportion of olaparib patients treated for second-line ovarian, fallopian tube and primary peritoneal cancer, compared to first-line therapy.
- The median age of patients initiating treatment with olaparib was 63 years old. The median age of initiating first- and second- line patients were similar.
- Actual utilisation of olaparib for the first-line therapy was different from estimated. The number of treated patients was greater than estimated, whereas the number of prescriptions supplied was lower than estimated.
The mean and median treatment duration for patients treated with olaparib in the first-line setting accounting for breaks in treatment was 9.17 months and 8.96 months, respectively. The treatment duration was less compared to the key trial, SOLO1.
Full Report
